• INNOVATION • QUALITY • EFFICIENCY
“As the Massachusetts life sciences cluster keeps growing, led by the cutting-edge research at our world-class hospitals and universities, the demand for out-sourced drug discovery and development platforms continues to increase,” said Robert K. Coughlin, President & CEO of Massachusetts Biotechnology Council (MassBio). “I’m confident that RxCelerate will help fill an important role in our state’s biopharma ecosystem.”
US operations will be led by Laura Hamilton, who has joined RxCelerate from the local industry trade association, MassBio: “There is huge demand for drug discovery and development services in the greater Boston area, and I look forward to introducing many more companies to the unique RxCelerate approach. I am certain RxCelerate can be as successful in Cambridge, MA, as they have been in Cambridge, UK.”
With Department for International Trade (DIT) support over the last two years, RxCelerate began to develop their international trade strategy and looked to expand their business abroad. DIT International Trade Advisers provided the company with local market insights, advice on export strategy and connected them to key target companies in the US, leading to a significant increase in export business in 2017, underpinning the opening of the US office.
Baroness Rona Fairhead, Minister of State for Trade and Export Promotion, said: “We are delighted to support an exciting UK-grown biotech company as it takes its first steps into new markets. The goal of our department is to support UK companies, large and small, sell ever-more of their products and services overseas. RxCelerate is a great example of what can be achieved by a UK company taking advantage of global demand.”
RxCelerate are headquartered on the Babraham Research Campus, home to more than 30 life science companies. “We are deeply integrated into the life sciences ecosystem. With our new US base, that ecosystem just got a whole lot bigger” said Dr Grainger.
RxCelerate is as an outsourced drug development platform specialising in bespoke experimental design with data-rich end-points. We can drive your asset through drug discovery, medicinal chemistry, preclinical research and beyond; maximising your chances of reaching the clinic.
RxCelerate offers comprehensive investigation packages and stand-alone assays with in-built flexibility, making it the perfect partner for both virtual, asset-centric companies and large pharmaceutical companies seeking to outsource elements of their project.
We combine client consultation with in-house expertise to ensure that our in vitro design and preclinical models are robust and information rich, improving both compound progression and translational capacity.
Choosing RxCelerate as your business partner will add financial and intellectual benefits to your drug candidate, helping to move it through IND within an accelerated time frame.